For more than a decade, Tristen has focused his consulting on helping clients achieve product success through navigation of product, pricing, and market access strategy. He has extensive experience across both rare and non-rare diseases in over 80 distinct indications. Clients value Tristen’s ability to quickly evaluate market opportunities and challenges, develop sound research plans to test and validate market assumptions, and provide comprehensive strategic recommendations to help guide commercialization efforts. He has led a variety of initiatives for pharmaceutical and medical technology companies such as marketing strategy, pricing strategy, pricing research, management and analysis of forecasts, market assessments, and product acquisition assessments.
Tristen also provides focused insights into gene therapies, having co-authored an article in JMCP entitled “Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold.”